Summary by Futu AI
In8bio, a clinical-stage biopharmaceutical company, has filed a prospectus related to the resale of up to 42,703,475 shares of common stock by selling stockholders. The shares include those issued in a private placement on December 13, 2023, and others pursuant to an Investors' Rights Agreement dated May 7, 2018. The company will not sell any shares or receive proceeds from the stockholders' sales but will receive proceeds from any exercised warrants for cash. The shares may be sold at market prices or negotiated prices through various methods, including underwriters, broker-dealers, or agents. In8bio's common stock is listed on the Nasdaq Global Market under the symbol 'INAB.' As of January 17, 2024, the stock was priced at $1.52 per share. The company, which focuses on gamma-delta T cell therapies for cancer, is considered an 'emerging growth company' and a 'smaller reporting company,' with certain reduced public company reporting requirements. The prospectus also highlights the risks associated with investing in In8bio's securities.